Wells Fargo
CYCN icon

Wells Fargo’s Cyclerion Therapeutics CYCN Stock Holding History

Wells Fargo’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15
Closed -$48 – 7020
2024
Q1 		$48 Hold
15
– – ﹤0.01% 6839
2023
Q4 		$50 Buy
15
+1
+7% +$3 ﹤0.01% 6930
2023
Q3 		$48 Hold
14
– – ﹤0.01% 6925
2023
Q2 		$58 Hold
14
– – ﹤0.01% 7018
2023
Q1 		$118 Sell
14
-104
-88% -$1.31K ﹤0.01% 6901
2022
Q4 		$1.55K Buy
118
+100
+556% +$1.18K ﹤0.01% 6067
2022
Q3 		$0 Sell
18
-2
-10% -$34 ﹤0.01% 6756
2022
Q2 		$0 Buy
20
+1
+5% +$14 ﹤0.01% 6900
2022
Q1 		$0 Hold
19
– – ﹤0.01% 7162
2021
Q4 		$0 Hold
19
– – ﹤0.01% 7298
2021
Q3 		$1K Buy
19
+3
+19% +$196 ﹤0.01% 6680
2021
Q2 		$1K Sell
16
-374
-96% -$23.4K ﹤0.01% 6639
2021
Q1 		$21K Sell
390
-2,136
-85% -$160K ﹤0.01% 6128
2020
Q4 		$154K Buy
2,526
+1,106
+78% +$75.4K ﹤0.01% 5191
2020
Q3 		$173K Sell
1,420
-314
-18% -$35.9K ﹤0.01% 5023
2020
Q2 		$205K Sell
1,734
-1,011
-37% -$84.5K ﹤0.01% 4892
2020
Q1 		$145K Buy
2,745
+569
+26% +$40.6K ﹤0.01% 4869
2019
Q4 		$118K Sell
2,176
-799
-27% -$74.6K ﹤0.01% 5218
2019
Q3 		$722K Buy
2,975
+1,197
+67% +$259K ﹤0.01% 4101
2019
Q2 		$408K Buy
+1,778
New +$503K ﹤0.01% 4519

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo's CYCN Position: Q2 2024 in Review

Wells Fargo sold out of Cyclerion Therapeutics (CYCN) in Q2 2024, closing a stake of 15 shares — an estimated $48 sold.

Wells Fargo first reported a position in CYCN in Q2 2019 and held it in 20 quarters. The position peaked at $722K in Q3 2019. 17 funds tracked by Wall St. Rank hold CYCN as of Q2 2024.

  • Wells Fargo reported no remaining Cyclerion Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 15 Cyclerion Therapeutics shares in Q2 2024, an estimated $48.
  • Wells Fargo first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 20 quarters.
  • Wells Fargo's Cyclerion Therapeutics position peaked at $722K in Q3 2019.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.